A monoclonal antibody TrkB receptor agonist as a potential therapeutic for huntington's disease

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Todd, Daniel ^b   Gowers, Ian ^b   Dowler, Simon J ^b   Wall, Michael D ^b   McAllister, George ^b   Fischer, David F ^b   Dijkstra, Sipke ^c   Fratantoni, Silvina A ^c   Van De Bospoort, Rhea ^c   Veenman Koepke, Jessica ^c   Flynn, Geraldine ^c   Arjomand, Jamshid ^a   Dominguez, Celia ^a   Munoz Sanjuan, Ignacio ^a   Wityak, John ^a   Bard, Jonathan A ^a  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b BioFocus DPI   (United Kingdom)

^c Galapagos   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDROXYFLAVONE; AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR AGONIST; CENTRAL NERVOUS SYSTEM AGENTS; CYCLOPEPTIDE; LM 22A 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 29D7; MONOCLONAL ANTIBODY 38B8; N ACETYLSEROTONIN; UNCLASSIFIED DRUG; BRAIN DERIVED NEUROTROPHIC FACTOR; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG SCREENING; EMBRYO; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VIVO STUDY; NERVE CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VALIDATION STUDY; AGONISTS; ANIMAL; CELL CULTURE; CELL DEATH; CELL LINE; CHEMISTRY; CORPUS STRIATUM; CYTOLOGY; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CELL LINE; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECEPTOR, TRKB; SIGNAL TRANSDUCTION;

EID: 84895136337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087923     Document Type: Article

References (44)

1. Martin JB, Gusella JF (1986) Huntington's disease. Pathogenesis and management. N Engl J Med 315: 1267-1276.
2. Vonsattel JP, Keller C, Cortes Ramirez EP (2011) Huntington's disease - neuropathology. Handb Clin Neurol 100: 83-100.
3. McFarland KN, Cha JH (2011) Molecular biology of Huntington's disease. Handb Clin Neurol 100: 25-81.
4. Shannon KM (2011) Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis. Handb Clin Neurol 100: 3-13.
5. Vonsattel JP, Keller C, Del Pilar Amaya M (2008) Neuropathology of Huntington's disease. Handb Clin Neurol 89: 599-618.
6. Harper PS (1999) Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. Philos Trans R Soc Lond B Biol Sci 354: 957-961.
7. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
8. Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 91: 5355-5358. (Pubitemid 24174325)
9. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549-558. (Pubitemid 27347244)
10. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993. (Pubitemid 27449140)
11. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810. (Pubitemid 39434070)
12. Sánchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421: 373-379. (Pubitemid 36157935)
13. Barbacid M (1994) The Trk family of neurotrophin receptors. J Neurobiol 25: 1386-1403.
14. Gentry JJ, Barker PA, Carter BD (2004) The p75 neurotrophin receptor: multiple interactors and numerous functions. Prog Brain Res 146: 25-39. (Pubitemid 37541373)
15. Ibanez CF, Simi A (2012) p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci 35: 431-440.
16. Pollack SJ, Harper SJ (2002) Small molecule Trk receptor agonists and other neurotrophic factor mimetics. Curr Drug Targets CNS Neurol Disord 1: 59-80.
17. Gines S, Bosch M, Marco S, Gavalda N, Diaz-Hernandez M, et al. (2006) Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 23: 649-658.
18. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, et al. (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 18: 225-238. (Pubitemid 351430396)
19. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498. (Pubitemid 32679077)
20. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, et al. (2007) Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27: 11758-11768. (Pubitemid 350006916)
21. Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 30: 14708-14718.
22. BDNF Study Group T (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52: 1427.
23. Longo FM, Massa SM (2013) Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov 12: 507-525.
24. Lin JC, Tsao D, Barras P, Bastarrachea RA, Boyd B, et al. (2008) Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates. PLoS ONE 3: e1900.
25. Qian MD, Zhang J, Tan X-Y, Wood A, Gill D, et al. (2006) Novel Agonist Monoclonal Antibodies Activate TrkB Receptors and Demonstrate Potent Neurotrophic Activities. The Journal of Neuroscience 26: 9394-9403. (Pubitemid 44396852)
26. Boyden TL, Guo F, Lagreca SD, Lorenz DA, Shanker RM, et al. (2007) Salts, prodrugs and formulations of 1-(5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d] pyrimidine-5-carbonyl)-2-methoxyphenyl)-3-(2,4-dichlorophenyl)urea. In: Organization WIP, editor.
27. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, et al. (2000) Sequential Treatment of SH-SY5Y Cells with Retinoic Acid and Brain-Derived Neurotrophic Factor Gives Rise to Fully Differentiated, Neurotrophic Factor-Dependent, Human Neuron-Like Cells. J Neurochem 75: 991-1003. (Pubitemid 30660487)
28. Kaltenbach LS, Bolton MM, Shah B, Kanju PM, Lewis GM, et al. (2010) Composite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions. J Biomol Screen 15: 806-819.
29. Wang J, Hancock MK, Dudek JM, Bi K (2008) Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases. Curr Chem Genomics 1: 27-33.
30. Groth RD, Mermelstein PG (2003) Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J Neurosci 23: 8125-8134. (Pubitemid 37082466)
31. Cazorla M, Arrang JM, Premont J (2011) Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br J Pharmacol 162: 947-960.
32. HD iPSC Consortium T (2012) Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes. Cell Stem Cell 11: 264-278.
33. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, et al. (2009) The antidepressant amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 16: 644-656.
34. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283: 1305-1322. (Pubitemid 28016506)
35. Jang SW, Liu X, Pradoldej S, Tosini G, Chang Q, et al. (2010) N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A 107: 3876-3881.
36. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, et al. (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A 107: 2687-2692.
37. Liu X, Chan CB, Qi Q, Xiao G, Luo HR, et al. (2012) Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression. J Med Chem 55: 8524-8537.
38. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, et al. (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120: 1774-1785.
39. Williams G, Williams EJ, Maison P, Pangalos MN, Walsh FS, et al. (2005) Overcoming the inhibitors of myelin with a novel neurotrophin strategy. J Biol Chem 280: 5862-5869. (Pubitemid 40280068)
40. Ochs G, Penn RD, York M, Giess R, Beck M, et al. (2000) A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 1: 201-206.
41. Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 72: 609-642. (Pubitemid 36930455)
42. Chen J, Chua KW, Chua CC, Yu H, Pei A, et al. (2011) Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett 499: 181-185.
43. Jiang M, Peng Q, Liu X, Jin J, Hou Z, et al. (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 22: 2462-2470.
44. Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, et al. (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PLoS One 8: e64037.